EMAIL DETAILS

Thank you!

Sent from my iPhone

> On 04 May 2016, at 2:55 pm, hbiden@rosemontseneca.com wrote:
>
> Will do
>
> RHB
> 202-333-1880
>
>> On May 4, 2016, at 1:16 PM, Kathleen Biden <kathleenbiden@mac.com> wrote:
>>
>> Thanks Hunt. Can you ask that they respond to Michelle in some way so she feels it was reviewed.
>>
>> Sent from my iPhone
>>
>>> On 04 May 2016, at 1:06 pm, hbiden@rosemontseneca.com wrote:
>>>
>>> Thanks- I'll forward on to right people.
>>>
>>> RHB
>>> 202-333-1880
>>>
>>>> On May 4, 2016, at 7:44 AM, Kathleen Biden <kathleenbiden@mac.com> wrote:
>>>>
>>>> I want to forward below to someone. Do you know who that would be? Thanks!
>>>>
>>>> Today actually looks like it might be the nicest day of the week.
>>>>
>>>> Sent from my iPhone
>>>>
>>>> Begin forwarded message:
>>>>
>>>>> From: "McGuire, Michelle" <MMcGuire@childrensnational.org>
>>>>> Date: 26 Apr 2016 6:34:18 pm GMT-4
>>>>> To: Biden Kathleen <kathleenbiden@mac.com>
>>>>> Subject: Moonshot Initiative and Children's CETI Program
>>>>> Dear Kathleen,
>>>>>
>>>>> It was great to see you at the DCVLP fundraising event last week. Thank you again for hosting such a lovely evening. As I mentioned when we spoke, my CEO and I and some of our key cancer researchers are very keen on connecting with the Moonshot Initiative and sharing our incredible game-changing research with the team.
>>>>>
>>>>> The Program for Cell Enhancement and Technologies for Immunotherapy (CETI) is an immunotherapy-focused program that currently supports over 10 novel clinical trials developed at Children’s National using innovative cell therapies to treat patients with cancer. Because of the unique, potentially life-saving therapies that are only available at Children’s National, the program receives upwards of 100 patient referrals annually from all over the USA, including Johns Hopkins as the biggest referrer. The results are more promising than current T-cell therapies – the study program allows for:
>>>>> · Broader application (i.e. inclusion of very diverse hard to treat population with promising results)
>>>>> · Higher efficacy
>>>>> · Less severe side effects (i.e. minimal toxicity)
>>>>> · Strong track record for moving quickly to translate clinical trials from mice to (wo)men
>>>>> I am attaching a one page overview of the program here as well.
>>>>>
>>>>> As I mentioned, Matt had reached out to Don Graves about our interest in briefing the Moonshot Initiative team on our efforts here at Children’s. Don had mentioned that his assistant would be in touch to discuss further, but it has been a week and I have not heard back so I was hoping you could follow-up so that we could close the loop and connect.
>>>>>
>>>>> Thank you so much Kathleen. This is really promising for kids and adults and it would be so impactful for us to be part of this multi-institutional effort.
>>>>>
>>>>> Xo
>>>>> Michelle
>>>>>
>>>>>
>>>>> Michelle McGuire
>>>>> Vice President & Chief of Staff
>>>>> Office of the President
>>>>> Children’s National Health System
>>>>> 111 Michigan Avenue, NW
>>>>> Washington, DC 20010
>>>>> Office: 202-476-2189
>>>>> Fax: 202-476-3096
>>>>> Cell: 312-859-1374
>>>>>
>>>>> Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.
>>>> <CETI-Program-Overview-Moonshot-Initiative.docx